Prior to screening, we investigated ALK inhibitor responses of ALK-mutated neuroblastoma cell lines harboring MYCN amplifications (KellyALKF1174L, LAN-5ALKR1275Q) or non-amplified MYCN (SH-SY5YALKF1174L) (Additional file 1 Fig. S1) to select a cell line and establish suitable ALKi concentrations for screening. The gene discussed is ALK; the disease is neuroblastoma.